MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2018 International Congress

    Retrospective study on a cohort of 285 PD patients: Does the side of onset influence the global clinical phenotype?

    G. Lazzeri, G. Franco, E. Monfrini, E. Frattini, I. Trezzi, L. Borellini, G. Ardolino, F. Cogiamanian, A. Di Fonzo (Milano, Italy)

    Objective: To describe demographic and clinical characteristics of a cohort of 285 consecutive PD patients and to understand the phenotypic differences of right onset (RPD)…
  • 2018 International Congress

    Lycopene ameliorates haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation

    S. Jamwal, P. Kumar (Baddi, India)

    Objective: The study was undertakento investigate the role of striatal neurotransmitters and neuroinflammatory cytokines in the neuroprotective effect of lycopene against haloperidol induced orofacial dyskinesia…
  • 2018 International Congress

    The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

    I. Frouni, D. Bedard, S. Belliveau, E. Bourgeois-Cayer, A. Hamadjida, P. Huot (Montreal, QC, Canada)

    Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A ) receptor antagonist EMD-281,014 at alleviating L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat.…
  • 2018 International Congress

    The BlueSky Project: monitoring motor and non-motor characteristics of people with Parkinson’s disease in the laboratory, a simulated apartment, and home and community settings

    K. Erb, J. Daneault, S. Amato, P. Bergethon, C. Demanuele, T. Kangarloo, S. Patel, V. Ramos, D. Volfson, P. Wacnik, H. Zhang, D. Karlin, H. Huggins, L. Soll, G. Costante, G. Vergara-Diaz, F. Parisi, J. Banghu, C. Brooks, C. Dethridge, A. Abrami, E. Bilal, V. Caravagio, S. Heisig, R. Norel, E. Pissadaki, J. Rice, B. Ho, K. Thomas, P. Bonato (Cambridge, MA, USA)

    Objective: We present data collected for the BlueSky Project which aims to develop novel assessments of motor and non-motor function using mobile and wearable technology.…
  • 2018 International Congress

    Final Safety Results of EASE LID 2 Study: Long Term Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients

    S. Isaacson, R. Pahwa, C. Tanner, R. Hauser, W. Oertel, R. Johnson, L. Felt, M.J. Stempien, R. Patni (Boca Raton, FL, USA)

    Objective: The primary objective of this study was the safety and tolerability of ADS-5102 in PD patients with dyskinesia. Secondary efficacy outcome measures included MDS-UPDRS,…
  • 2018 International Congress

    Quantifying the Reproducibility of an In Vivo Assay: Examination of Historical Amantadine Effects in the macaque Model of L-DOPA-Induced Dyskinesia

    E. Pioli, P. Stanley, W. Ko, Q. Li, R. Kozak, P. Popiolek, E. Bezard (Manchester, United Kingdom)

    Objective: This study was designed to assess the reproducibility of the amantadine anti-dyskinetic effect in the MPTP L-DOPA-Induced Dyskinesia (LID) macaque model for soundly defining…
  • 2018 International Congress

    Objective Data in Parkinson’s Disease: A description of over 20,000 Parkinson’s symptom scores across the world using the Personal KinetiGraph (PKG)

    P. Lynch, R. Pahwa, F. Bergquist, M. Horne (Minnetonka, MN, USA)

    Objective: The objective of this population study was to update & expand upon previous research [8] done to describe the objective symptom scores from a…
  • 2018 International Congress

    Emulating the natural timing of dopamine receptor activation in Parkinson’s Disease

    J. Reynolds, B. Hyland, J. Wickens, E. Tan (Dunedin, New Zealand)

    Objective: To emulate physiological dopamine receptor activation, in order to restore temporal patterns of dopamine-like signalling and normalise function in the striatum in Parkinson's disease.…
  • 2018 International Congress

    Does altering medication to avoid dyskinesia positively alters the breadth of the motor repertoire of patients with Parkinson’s disease? A pilot study

    S. Bogard, E. Goubault, K. Lebel, C. Duval (Montreal, QC, Canada)

    Objective: The aim of this study was to assess the level of drug-induced dyskinesia (DID), the presence of other motor symptoms of PD, and the…
  • 2018 International Congress

    The Levodopa Response Trial and the Parkinson Disease Digital Biomarker Challenge: Monitoring symptoms of Parkinson’s disease in the lab and home using wearable sensors

    J. Daneault, G. Vergara-Diaz, G. Costante, E. Fabara, G. Ferreira-Carvalho, F. Golabchi, F. Parisi, S. Sapienza, Y. Chae, P. Snyder, P. Aubin, P. Banda, D. Brunner, R. Dorsey, L. Mangravite, W. Marks, E. Neto, U. Rubin, E. Soderberg, D. Daeschler, S. Moore, S. Sieberts, L. Omberg, P. Bonato, The Parkinson's Disease Digital Biomarker DREAM Challenge Consortium (Newark, NJ, USA)

    Objective: To leverage a community of researchers and shared wearable data to develop algorithms to estimate the severity of PD specific symptoms. Background: People with…
  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 40
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley